Recombinant human parathyroid hormone 1-34: Pharmacokinetics, tissue distribution and excretion in rats

International Journal of Pharmaceutics

Volumn 317, Issue 2, 2006, Pages 144-154

  Hu, Zeping ^a,b   Niu, Huisheng ^c   Yang, Xiaoxia ^a   Li, Huaifen ^c   Sang, Guowei ^b   Li, Bo ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Bioavailability; Distribution; Excretion; Pharmacokinetics; Recombinant human parathyroid hormone (1 34)

Indexed keywords

IODINE 125; PARATHYROID HORMONE[1-34]; RECOMBINANT HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FECES; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; BILE; FECES; FEMALE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IODINE RADIOISOTOPES; MALE; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 33745220955     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.03.005     Document Type: Article

References (75)

1. Akaike H. An information criterion (AIC). Math. Sci. 14 (1976) 5-9
2. Alexander J.M., Bab I., Fish S., Muller R., Uchiyama T., Gronowicz G., Nahounou M., Zhao Q., White D.W., Chorev M., Gazit D., and Rosenblatt M. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J. Bone Miner. Res. 16 (2001) 1665-1673
3. Andreassen T.T., and Cacciafesta V. Intermittent parathyroid hormone treatment enhances guided bone regeneration in rat calvarial bone defects. J. Craniofac. Surg. 15 (2004) 424-427 (Discussions 428-429)
4. Andreassen T.T., Ejersted C., and Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J. Bone Miner. Res. 14 (1999) 960-968
5. Bergeron J.J., Tchervenkov S., Rouleau M.F., Rosenblatt M., and Goltzman D. In vivo demonstration of receptors in rat liver to the amino-terminal region of parathyroid hormone. Endocrinology 109 (1981) 1552-1559
6. Binkley N., and Krueger D. Combination therapy for osteoporosis: considerations and controversy. Curr. Rheumatol. Rep. 7 (2005) 61-65
7. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., Dore R.K., Correa-Rotter R., Papaioannou A., Cumming D.C., and Hodsman A.B. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87 (2002) 4528-4535
8. Brixen K.T., Christensen P.M., Ejersted C., and Langdahl B.L. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin. Pharmacol. Toxicol. 94 (2004) 260-270
9. Brown L.R. Commercial challenges of protein drug delivery. Expert Opin. Drug Delivery 2 (2005) 29-42
10. Codrons V., Vanderbist F., Ucakar B., Preat V., and Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93 (2004) 1241-1252
11. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Preat V., and Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 92 (2003) 938-950
12. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch. Intern. Med. 162 (2002) 2297-2309
13. Daugaard H., Egfjord M., Lewin E., and Olgaard K. Metabolism of N-terminal and C-terminal parathyroid hormone fragments by isolated perfused rat kidney and liver. Endocrinology 134 (1994) 1373-1381
14. Deal C., Omizo M., Schwartz E.N., Eriksen E.F., Cantor P., Wang J., Glass E.V., Myers S.L., and Krege J.H. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20 (2005) 1905-1911
15. Ejersted C., Andreassen T.T., Hauge E.M., Melsen F., and Oxlund H. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17 (1995) 507-511
16. Finkelstein J.S., and Arnold A.L. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J. Clin. Endocrinol. Metab. 84 (1999) 1214-1219
17. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
18. Finkelstein J.S., Klibanski A., Arnold A.L., Toth T.L., Hornstein M.D., and Neer R.M. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 280 (1998) 1067-1073
19. Finkelstein J.S., Klibanski A., Schaefer E.H., Hornstein M.D., Schiff I., and Neer R.M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 331 (1994) 1618-1623
20. Fox J.A., Hotaling T.E., Struble C., Ruppel J., Bates D.J., and Schoenhoff M.B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 279 (1996) 1000-1008
21. Fraher L.J., Klein K., Marier R., Freeman D., Hendy G.N., Goltzman D., and Hodsman A.B. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J. Clin. Endocrinol. Metab. 80 (1995) 60-64
22. Fraker P.J., and Speck J.C. Protein and cell membrane iodination with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril. Biochem. Biophys. Res. Commun. 80 (1978) 849-857
23. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., and Hock J.M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33 (2003) 372-379
24. Garces C., and Garcia L.E. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 54 (2006) 47-54
25. Gardella T.J., and Juppner H. Interaction of PTH and PTHrP with their receptors. Rev. Endocr. Metab. Disord. 1 (2000) 317-329
26. Habener J.F., Rosenblatt M., and Potts Jr. J.T. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol. Rev. 64 (1984) 985-1053
27. Hirano T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14 (1999) 536-545
28. Holzer G., Majeska R.J., Lundy M.W., Hartke J.R., and Einhorn T.A. Parathyroid hormone enhances fracture healing. A preliminary report. Clin. Orthop. (1999) 258-263
29. Hruska K.A., Korkor A., Martin K., and Slatopolsky E. Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. J. Clin. Invest. 67 (1981) 885-892
30. Hunziker J., Wronski T.J., and Miller S.C. Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. J. Dent. Res. 79 (2000) 1431-1438
31. Iwaniec U.T., Mosekilde L., Mitova-Caneva N.G., Thomsen J.S., and Wronski T.J. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology 143 (2002) 2515-2526
32. Jerome C.P., Burr D.B., Van Bibber T., Hock J.M., and Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28 (2001) 150-159
33. Jolivette L.J., and Ward K.W. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: molecular properties associated with extrapolative success or failure. J. Pharm. Sci. 94 (2005) 1467-1483
34. Kent G.N., Loveridge N., Reeve J., and Zanelli J.M. Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin. Sci. (London) 68 (1985) 171-177
35. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., and Recker R.R. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132 (1993) 1577-1584
36. Koch C.A. Rapid increase in bone mineral density in a child with osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34. Exp. Clin. Endocrinol. Diabetes 109 (2001) 350-354
37. Kohno T., Murasugi N., Sakurai H., Watabe K., Nakamuta H., Koida M., Sugie Y., Nomura M., and Yanagawa A. Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human. J. Clin. Lab. Anal. 12 (1998) 268-275
38. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., and Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85 (2000) 3069-3076
39. Leone-Bay A., Sato M., Paton D., Hunt A.H., Sarubbi D., Carozza M., Chou J., McDonough J., and Baughman R.A. Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18 (2001) 964-970
40. Li M., Healy D.R., Li Y., Simmons H.A., Gao F., Ke H.Z., Lu B., Owen T.A., and Thompson D.D. A comparison of the anabolic effects of rat and bovine parathyroid hormone (1-34) in ovariectomized rats. J. Musculoskelet. Neuronal Interact. 2 (2001) 77-83
41. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D., and Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350 (1997) 550-555
42. Lindsay R., Nieves J., Henneman E., Shen V., and Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J. Clin. Endocrinol. Metab. 77 (1993) 1535-1539
43. Lotinun S., Evans G.L., Bronk J.T., Bolander M.E., Wronski T.J., Ritman E.L., and Turner R.T. Continuous parathyroid hormone induces cortical porosity in the rat: effects on bone turnover and mechanical properties. J. Bone Miner. Res. 19 (2004) 1165-1171
44. Maier G.W., Kreis M.E., Renn W., Pereira P.L., Haring H.U., and Becker H.D. Parathyroid hormone after adenectomy for primary hyperparathyroidism. A study of peptide hormone elimination kinetics in humans. J. Clin. Endocrinol. Metab. 83 (1998) 3852-3856
45. Mannstadt M., Juppner H., and Gardella T.J. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Physiol. 277 (1999) F665-F675
46. Martin K.J., Hruska K.A., Freitag J.J., Klahr S., and Slatopolsky E. The peripheral metabolism of parathyroid hormone. N. Engl. J. Med. 301 (1979) 1092-1098
47. Mashiba T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28 (2001) 538-547
48. Modi N.B. Pharmacokinetics and pharmacodynamics of recombinant proteins and peptides. J. Contr. Release 29 (1994) 269-281
49. Mosekilde L., Danielsen C.C., Sogaard C.H., McOsker J.E., and Wronski T.J. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model. Bone 16 (1995) 223-230
50. Mosekilde L., Tornvig L., Thomsen J.S., Orhii P.B., Banu M.J., and Kalu D.N. Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia. Bone 26 (2000) 643-651
51. Nakajima A., Shimoji N., Shiomi K., Shimizu S., Moriya H., Einhorn T.A., and Yamazaki M. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J. Bone Miner. Res. 17 (2002) 2038-2047
52. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., and Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
53. Neuman W.F., Neuman M.W., Sammon P.J., Simon W., and Lane K. The metabolism of labeled parathyroid hormone. III. Studies in rats. Calcif Tissue Res. 18 (1975) 251-261
54. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., and Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283 (1997) 46-58
55. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.M., Clancy A.D., and Gaich G.A. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18 (2003) 9-17
56. Podbesek R., Edouard C., Meunier P.J., Parsons J.A., Reeve J., Stevenson R.W., and Zanelli J.M. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112 (1983) 1000-1006
57. Potts Jr. J.T., Kronenberg H.M., and Rosenblatt M. Parathyroid hormone: chemistry, biosynthesis, and mode of action. Adv. Protein Chem. 35 (1982) 323-396
58. Putney S.D., and Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16 (1998) 153-157
59. Qin L., Raggatt L.J., and Partridge N.C. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab. 15 (2004) 60-65
60. Quattrocchi E., and Kourlas H. Teriparatide: a review. Clin. Ther. 26 (2004) 841-854
61. Reeve J. Recombinant human parathyroid hormone. BMJ 324 (2002) 435-436
62. Reeve J., Hesp R., Williams D., Hulme P., Klenerman L., Zanelli J.M., Darby A.J., Tregear G.W., and Parsons J.A. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1 (1976) 1035-1038
63. Sato M., Zeng G.Q., and Turner C.H. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 138 (1997) 4330-4337
64. Segre G.V., Perkins A.S., Witters L.A., and Potts Jr. J. Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes. J. Clin. Invest. 67 (1981) 449-457
65. Suzuki Y., Yabuta M., and Ohsuye K. High-level production of recombinant human parathyroid hormone 1-34. Appl. Environ. Microbiol. 64 (1998) 526-529
66. Takagi A., Masuda H., Takakura Y., and Hashida M. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther. 275 (1995) 537-543
67. Tang L., Persky A.M., Hochhaus G., and Meibohm B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93 (2004) 2184-2204
68. Tian J., Smogorzewski M., Kedes L., and Massry S.G. Parathyroid hormone-parathyroid hormone related protein receptor messenger RNA is present in many tissues besides the kidney. Am. J. Nephrol. 13 (1993) 210-213
69. Turner C.H., Burr D.B., Hock J.M., Brommage R., and Sato M. The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. Adv. Exp. Med. Biol. 496 (2001) 165-179
70. Urena P., Kong X.F., Abou-Samra A.B., Juppner H., Kronenberg H.M., Potts Jr. J.T., and Segre G.V. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133 (1993) 617-623
71. Uzawa T., Hori M., Ejiri S., and Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 16 (1995) 477-484
72. Vahle J.L., Sato M., Long G.G., Young J.K., Francis P.C., Engelhardt J.A., Westmore M.S., Linda Y., and Nold J.B. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30 (2002) 312-321
73. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M., Gaich G.A., Dalsky G.P., and Myers S.L. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18 (2003) 539-543
74. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., and Lindsay R. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520
75. Zhou H., Shen V., Dempster D.W., and Lindsay R. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J. Bone Miner. Res. 16 (2001) 1300-1307